iifl-logo

Glenmark Pharmaceuticals Ltd Share Price Live

1,971.7
(-2.91%)
Sep 26, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open2,012
  • Day's High2,012
  • 52 Wk High2,284.8
  • Prev. Close2,030.7
  • Day's Low1,956.7
  • 52 Wk Low 1,275.5
  • Turnover (lac)18,227.71
  • P/E30.59
  • Face Value1
  • Book Value880.02
  • EPS66.4
  • Mkt. Cap (Cr.)55,641.53
  • Div. Yield0.12
View All Historical Data
Loading...
  • Open1,719.7
  • Day's High1,743.7
  • Spot1,732
  • Prev. Close1,719.4
  • Day's Low1,719
  • ViewShort Covering
  • Market Lot325
  • OI(Chg %)-1,15,700 (-5.43%)
  • Roll Over%2.66
  • Roll Cost1.22
  • Traded Vol.24,39,450 (-23.34%)
View More Futures
Loading...

Glenmark Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

2,012

Prev. Close

2,030.7

Turnover(Lac.)

18,227.71

Day's High

2,012

Day's Low

1,956.7

52 Week's High

2,284.8

52 Week's Low

1,275.5

Book Value

880.02

Face Value

1

Mkt Cap (₹ Cr.)

55,641.53

P/E

30.59

EPS

66.4

Divi. Yield

0.12

Glenmark Pharmaceuticals Ltd Corporate Action

22 Aug 2025

12:00 AM

AGM

Announcement Date: 22 Aug, 2025

arrow

22 Sep 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Glenmark Pharmaceuticals Ltd NEWS AND UPDATE

Top Stocks for Today - 25th September 2025

Here are some of the stocks that may see significant price movement today: Polycab India, Tata Steel, Dalmia Bharat, etc.

25 Sep 2025|06:57 AM
Read More
Top Stocks for Today - 23rd September 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Rail Vikas Nigam, Birla Corp, etc.

23 Sep 2025|07:01 AM
Read More
Glenmark subsidiary gets $700 Million in licensing deal; stock gains

At around 2.19 PM, Glenmark Pharma was trading 2.97% higher at ₹2,112.90 per piece, against the previous close of ₹2,051.90 on NSE.

9 Sep 2025|02:31 PM
Read More
Glenmark Pharma Q1 Net Profit Falls 86% YoY to ₹47 Crore

Operating performance was slightly weaker, with EBITDA dipping 1.4% to ₹580 crore from ₹588.2 crore.

18 Aug 2025|01:03 PM
Read More
Top Stocks for Today - 18th August 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharmaceuticals, Vedanta, Inox Wind, etc.

18 Aug 2025|08:14 AM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Glenmark Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

28 Sep, 2025|03:59 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 46.64%

Foreign: 0.00%

Indian: 46.64%

Non-Promoter- 38.29%

Institutions: 38.29%

Non-Institutions: 15.05%

Custodian: 0.00%

Share Price

Glenmark Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2025Mar-2024Mar-2023Mar-2022

Equity Capital

28.22

28.22

28.22

28.22

Preference Capital

0

0

0

0

Reserves

24,475.74

22,942.4

17,849.25

16,710.37

Net Worth

24,503.96

22,970.62

17,877.47

16,738.59

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

7,567.93

6,712.63

6,403.23

7,989.23

yoy growth (%)

12.74

4.83

-19.85

30.64

Raw materials

-2,999.45

-2,665.99

-2,378.59

-2,425.49

As % of sales

39.63

39.71

37.14

30.35

Employee costs

-1,107.39

-1,072.32

-1,021.92

-914.47

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

1,869.86

1,516.09

1,218.82

2,789.34

Depreciation

-150.81

-138.53

-118.2

-104.93

Tax paid

-294.31

-180.09

-204.47

-412.28

Working capital

463.74

-1,507.52

-180.36

1,492.86

Other operating items

View Cash Flow
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

12.74

4.83

-19.85

30.64

Op profit growth

44.93

-3.21

-53.51

64.2

EBIT growth

20.49

25.73

-52.08

65.02

Net profit growth

21.77

33.53

-52.61

44.21

View Ratios
Particulars (Rupees in Crores.)Mar-2025Mar-2024Mar-2023Mar-2022Mar-2021

Gross Sales

13,145.84

11,635.46

11,431.94

12,174.2

10,806.03

Excise Duty

0

0

0

0

0

Net Sales

13,145.84

11,635.46

11,431.94

12,174.2

10,806.03

Other Operating Income

175.9

177.64

151.3

130.71

137.9

Other Income

113.72

1,237.32

755.86

166.67

94.76

Glenmark Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,586.7

78.423,90,611.73753.530.985,566.68101.44

Divis Laboratories Ltd

DIVISLAB

5,689.5

67.031,56,589.35570.512,357561.08

Cipla Ltd

CIPLA

1,499.4

23.611,21,954.711,303.131.064,501.66397.38

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,561

60.141,19,555.565510.172,567224.34

Dr Reddys Laboratories Ltd

DRREDDY

1,253.1

15.441,06,396.562,961.20.637,788.7345.74

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Glenmark Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Chairman / Executive Director / M D / Promoter

Glenn Saldanha

ED / WTD / Promoter

Cheryl Pinto

ED / President / Global CFO

Anurag Mantri

Non Executive Director

B E Saldanha

Independent Non Exe. Director

Sona Saira Ramasastry

Independent Non Exe. Director

Dipankar Bhattacharjee

Independent Non Exe. Director

V R Iyer

Independent Non Exe. Director

Pradeep Kumar Sinha

Company Sec. & Compli. Officer

Harish Kuber

Registered Office

B/2 Mahalaxmi Chambers,

22 Bhulabhai Desai Road,

Maharashtra - 400026

Tel: 91-22-40189999

Website: http://www.glenmarkpharma.com

Email: complianceofficer@glenmarkpharma.com

Registrar Office

Karvy Selenium Tow-B,

31&32 Financial Dist, Nanakramguda,

Hyderabad-500032

Tel: 91-40-67162222

Website: www.kfintech.com

Email: einward.ris@kfintech.com

Summary

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological enti...
Read More

Company FAQs

What is the Glenmark Pharmaceuticals Ltd share price today?

The Glenmark Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1971.7 today.

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Pharmaceuticals Ltd is ₹55641.53 Cr. as of 26 Sep ‘25

What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd?

The PE and PB ratios of Glenmark Pharmaceuticals Ltd is 30.59 and 2.34 as of 26 Sep ‘25

What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?

The 52-week high/low is the highest and lowest price at which a Glenmark Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Glenmark Pharmaceuticals Ltd is ₹1275.5 and ₹2284.8 as of 26 Sep ‘25

What is the CAGR of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd's CAGR for 5 Years at 33.30%, 3 Years at 76.71%, 1 Year at 20.22%, 6 Month at 37.14%, 3 Month at 18.26% and 1 Month at 3.81%.

What is the shareholding pattern of Glenmark Pharmaceuticals Ltd?

The shareholding pattern of Glenmark Pharmaceuticals Ltd is as follows:
Promoters - 46.65 %
Institutions - 38.30 %
Public - 15.06 %
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.